Improving access to gene therapy for rare diseases.

Area of Science:

• Genetics
• Medical Science
• Pharmacology

Background:

• Gene therapy offers effective treatments for rare inherited diseases like immunodeficiencies, metabolic disorders, haemoglobinopathies, and blindness.
• Despite successful clinical trials, widespread patient access to these advanced therapy medicinal products (ATMPs) remains limited.

Purpose of the Study:

• To identify key non-medical challenges hindering gene therapy accessibility for rare diseases.
• To propose potential solutions for improving the availability of gene therapies.

Main Methods:

• This perspective reviews existing literature and expert insights on gene therapy development and access.
• Analysis of commercial viability, manufacturing complexities, and regulatory hurdles for ATMPs targeting rare and ultra-rare conditions.

Main Results:

• Limited commercial interest in ultra-rare disease therapies and high development costs are significant barriers.
• Complex manufacturing processes for ATMPs and navigating diverse international regulatory landscapes pose unique challenges.
• These factors collectively restrict patient access to potentially life-changing gene therapies.

Conclusions:

• Overcoming non-medical barriers is essential to realize the full potential of gene therapy for rare diseases.
• Streamlining regulatory pathways and fostering commercial interest are key to improving access.
• Collaborative efforts are needed to ensure equitable availability of advanced gene therapies.